FDA granted Orphan Drug Designation to BAL0891, a therapeutic targeting the TTK protein, developed by Hanmi Pharmaceutical.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Orphan Drug Designation to BAL0891, a therapeutic targeting the TTK protein, developed by Hanmi Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hanmi Pharmaceutical
South Korean pharmaceutical company
Nothing else this week.
-
TTK
Nothing else this week.
- FDA